Immunotherapy has made a great breakthrough in recent years, with antibody therapy at the core of this breakthrough. Traditional antibody therapies target cell membrane surface antigens (such as PD-1 and PD-L1) or soluble antigens. However, many tumor-associated antigens (for example, RAS, P53, and WT1) are intracellular, which is a limitation of antibody therapy. Instead, intracellular antigens are recognized by T cell receptors (TCRs) that enhance cellular immunity by identifying specific major histocompatibility complexes (MHC) and the presented MHC-antigen-peptide (MAP) on the tumor cell surface. However, these TCRs often have a low affinity for the corresponding antigen, which can result in tumor cell immune evasion.
Biocytogen’s TCR-mimic antibody technology platform aims to effectively replace the traditional TCR response by discovering high-affinity antibodies with greater specificity for intracellular antigens. Learn more:
Advantages of Biocytogen’s TCR-mimic Antibody Platform
- Biocytogen’s unique HLA/RenMab mice, combined with our high-throughput antibody screening platform, enables a one-step process to generate fully human antibodies in vivo that identify human MAPs with high affinity.
- The antibodies selected through screening have better affinity and specificity than TCRs.
- The in situ large-fragment replacement and modification in RenMab mice ensures the diversity of antibody sequences.
- Our discovery process involves high-throughput screening in shortened timelines using the Beacon Optofluidic System and subsequent sequencing.
- The fully antibody sequences obtained by the TCR-mimic antibody technology platform provide more candidates for subsequent antibody-related drugs, CAR-T, TCR-T and other fields. It provides more intracellular targets for targeted clearance of specific abnormal cells such as tumor cells, infected cells and senescent cells. In addition, TCR-like blocking antibodies can also be utilized to spare cell populations that are attacked by autoimmune disease, so as to avoid damage to normal tissues.
Progress of Biocytogen’s TCR-mimic Antibody Development